iOmx Therapeutics

Fraunhofer Strasse 13, 4th Floor
Martinsried/ Munich
Bayern
82152
Germany

Tel: 49-0-89-8999-7090-0

About iOmx Therapeutics

iOmx is a dynamic biotech company developing novel immuno-oncology drugs. The Company is well financed by an international consortium of leading life science investors. iOmx focuses on innovation-driven research to advance its proprietary early-stage novel immune-checkpoint molecules through pre-clinical and clinical development.
YEAR FOUNDED:
2016
LEADERSHIP:
Co-Founder and CEO: David S. Joseph
CMO: Elizabeth A. Perkett
Chief Science Advisor: Graham S. Timmins, PH.D.
Senior Vice President, Product Development: David Karshmer
Vice President, Product Management: John Maynard
Vice President, Finance: Matt Culler
JOBS:
Please click here for iOmx job opportunities.
CLINICAL:
Please click here for iOmx's pipeline.

9 articles about iOmx Therapeutics

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024

4/3/2024

iOmx Therapeutics AG announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023

3/15/2023

iOmx Therapeutics AG today announced that its high-throughput target discovery platform, myeloid iOTargTM, will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022

4/7/2022

iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, announced the presentation of new preclinical data for its lead program IMT-07 with product candidate OMX-0407, a first-in-class oral SIK3 inhibitor.
iOmx Therapeutics Raises EUR 65 million in Series B Round

10/5/2021

iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million.
iOmx Therapeutics Enhances Supervisory Board

8/25/2020

Gerald Moeller, Ph.D., Elected Chairman of Supervisory Board; Rainer Strohmenger, MD, and Shinichiro Fuse, Ph.D., Named Supervisory Board Members
iOmx Therapeutics to Present at Biotech Showcase 2020

12/16/2019

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, announced today that its Chief Executive Officer Apollon Papadimitriou, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square in San Francisco.
iOmx Therapeutics Strengthens Executive Management Team and Supervisory Board

10/9/2019

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced significant changes to the company's executive management team. Apollon Papadimitriou, Ph.D. was appointed as chief executive officer and Marcus Irsfeld as chief financial officer
iOmx Therapeutics Announces Discovery of Novel, Druggable Immune-Checkpoint Targets

9/26/2019

iOmx Therapeutics AG (iOmx) announced the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company's proprietary, high-throughput genetic screening platform, iOTarg™.
German Immuno-Oncology Upstart iOmx Therapeutics Bags EUR 40 Million Series A

9/22/2016